Ionis Pharmaceuticals, Inc. Common Stock
IONS
$26.58
-2.35%
Ionis Pharmaceuticals is the pioneer and leading developer of antisense oligonucleotide technology, discovering and commercializing RNA-targeted medicines across cardiovascular, metabolic, neurological, and rare disease areas, with a marketed portfolio that includes partner-led Spinraza, Qalsody, Wainua, and Tegsedi alongside its own 2025 launches Tryngolza (FCS) and Dawnzera (HAE). The company occupies a distinctive platform position in biotechnology — it monetizes its drug-discovery engine through a deep web of pharma partnerships (Biogen, AstraZeneca, Novartis, GSK) that generate royalties and milestone payments while increasingly attempting to capture value directly through independent commercial launches. The current investor narrative has turned sharply negative: a 2026 cardiovascular pipeline failure, a slower-than-expected Tryngolza launch, and competitive pressure from Arrowhead have driven the stock down roughly 58% over the past year and 63% year-to-date, culminating in a violent post-Q3 selloff in early November. Bulls point to Dawnzera's strong early growth, positive Phase III readouts for two partnered programs, a fresh FDA approval for Zanvastro in Alexander disease, and a fortress cash position as evidence the platform remains intact, while bears question the commercial execution and the binary risk embedded in the pipeline.…
IONS
Ionis Pharmaceuticals, Inc. Common Stock
$26.58
Related headlines
Investment Opinion: Should I buy IONS Today?
Rating: Hold with a speculative-optionality bias. The core thesis is that Ionis's antisense platform remains scientifically validated — fresh Phase III wins for two partnered programs, an FDA approval for Zanvastro, and a 98.63% gross margin — but the company has not yet proven it can commercialize on its own, with royalties of $80.6 million still exceeding product revenue of $48.3 million and a slower-than-expected Tryngolza ramp driving a 58.39% one-year decline to $29.06. The 21 Buy / 4 Hold / 0 Sell consensus and $68.48 average target (+136% upside) anchor the view that the selloff has overshot, but the November 9-10 reiterations largely embed pre-selloff assumptions, so the Street's bullishness is a lagging signal rather than confirmation. Supporting evidence is mixed but tilts toward asymmetric reward: revenue grew 54.88% YoY to $242.7 million in Q3 2026, gross margin is 98.63%, the current ratio of 3.83 provides near-term liquidity, and even the $41.00 analyst low target sits 41% above the current price. Against that, TTM free cash flow is -$616.3 million, cash fell to $296.3 million from $782.6 million, debt-to-equity is 5.35, and the -40.47% operating margin shows losses widening per share (-$0.66 in Q3 vs -$0.56 in Q1) even as revenue grows. The biggest risks that could invalidate the thesis are a dilutive equity raise at depressed prices, continued Tryngolza/Dawnzera commercial disappointment against Arrowhead competition, and a partnered Phase III failure that removes milestone income. This Hold would upgrade to Buy if product revenue overtakes the $80.6 million royalty line or if a financing is completed on non-punitive terms, and would downgrade to Sell on a decisive break below the $27.25 52-week low or a cash balance falling below roughly $150 million without a funding plan. On valuation, the 13.41x P/S is near the low end of the 9x-67x historical band and EV/Sales of 5.28x is modest, so the stock is cheap relative to its own history but not obviously cheap on absolute sales multiples given execution risk — fairly valued to modestly undervalued versus history, but a bet on pipeline optionality rather than a defensible earnings multiple.
Sign up to view all
IONS 12-Month Price Forecast
The forward view is genuinely two-sided: the platform is validated and the 13.41x P/S is near the low end of its 9x-67x historical band, but the company has not demonstrated it can commercialize independently, and a $616.3 million cash burn against $296.3 million of cash makes financing the dominant near-term variable. The 50% base-case weight reflects that the most likely path is a dilutive raise that caps upside near the $41-$55 range rather than either a violent re-rating or a collapse below $27.25. Analyst sentiment is strongly bullish but stale, so I weight the operating data — widening per-share losses and product revenue trailing royalties — more heavily than the $68.48 target. I would upgrade to bullish if product revenue overtakes royalties or a financing lands on non-punitive terms, and downgrade to bearish on a decisive break below $27.25 or a cash balance below roughly $150 million without a funding plan.
Wall Street consensus
Coverage is broad and, on the surface, overwhelmingly bullish: 23 analysts rate the stock, with 21 Buy, 4 Hold, and 0 Sell, producing a consensus recommendation of "buy" and a mean rating of 1.64 (where 1.0 is a strong buy). The average target price of $68.48 implies roughly +136% upside from the current $29.06 — an extraordinary gap that signals either a deep disconnect between Street models and market pricing or stale targets that have not yet caught up to the November collapse. The institutional ratings flow shows the latter is partly at play: the most recent actions (November 9-10) were almost uniformly reiterations of Overweight/Buy/Outperform by Morgan Stanley, Wells Fargo, TD Cowen, HC Wainwright, RBC, Oppenheimer, and Needham, with Goldman maintaining Neutral — but the upgrades earlier in the fall (BMO to Outperform on October 22, UBS to Buy on October 15) predate the Q3 print and the subsequent gap-down, suggesting many targets embed pre-selloff assumptions. The consensus leans strongly bullish, but the failure of that bullishness to arrest a 58% decline is itself a warning about the reliability of the current target set. The target range is exceptionally wide — from a low of $41.00 to a high of $105.00, a 2.6x spread — which signals very high uncertainty and low conviction in any single outcome. The $105 high target likely assumes full pipeline validation: a successful Tryngolza and Dawnzera commercial ramp, multiple partnered Phase III wins converting to milestones and royalties, and a return to profitability that justifies a premium platform multiple. The $41 low target — still 41% above the current price — appears to price in continued commercial disappointment, margin compression from the commercial build-out, and perhaps a dilutive financing, yet even the bear case sits well above the market, implying the Street views the selloff as overdone. The wide dispersion, heavy short interest (8.0 days-to-cover), and the fact that even the lowest target implies meaningful upside collectively argue that the market is pricing a worse outcome than any published analyst model — a setup where a single positive catalyst (Dawnzera data, a partnership milestone, or a Tryngolza inflection) could force a violent re-rating, but where the burden of proof now rests squarely on execution.
Bulls vs Bears: IONS Investment Factors
The bear case currently has stronger evidence: the market is pricing a worse outcome than any published analyst model, and the operating data — widening per-share losses, $616.3 million of TTM cash burn, and product revenue still trailing royalties — justify much of that skepticism. The bull case rests on optionality rather than demonstrated execution: a 98.6% gross margin, a validated platform with fresh Phase III wins and an FDA approval, and a $68.48 average target that implies +136% upside if even part of the pipeline converts. The single most important tension is whether Dawnzera and Tryngolza can scale product revenue past the $80.6 million royalty line before the cash pile forces a dilutive raise — resolve that in Ionis's favor and the de-rating reverses violently; fail, and the $27.25 low is only a waypoint. The 2.6x spread between the $41 low and $105 high target confirms that even the Street has low conviction in any single outcome.
Bullish
- Analyst targets imply massive upside: All 23 covering analysts rate IONS Buy or Hold with zero Sells, and the $68.48 average target sits roughly +136% above the $29.06 price. Even the $41.00 low target is 41% above the current quote, meaning no published model prices the stock where the market has taken it.
- Dawnzera launch gaining traction: Dawnzera's strong early growth is repeatedly cited as the counterweight to the slower Tryngolza ramp, and product revenue of $48.3 million is now building on two independent launches rather than one. This is the first evidence Ionis can commercialize on its own rather than relying solely on partners.
- Platform validated by Phase III wins: Positive late-stage results for two partnered programs in September 2026 plus the FDA approval of Zanvastro for Alexander disease confirm the antisense engine still produces approvable drugs. These partnered wins carry milestone and royalty value even without Ionis bearing full commercial cost.
- Revenue growing 54.9% YoY with 98.6% gross margin: Q3 2026 revenue of $242.7 million rose 54.88% from $156.7 million a year earlier, and gross profit of $239.4 million on that revenue reflects a 98.63% gross margin. The royalty-style cost structure means incremental revenue drops through at almost pure margin once operating expenses are covered.
Bearish
- Commercial execution is failing: Royalties of $80.6 million still exceed product revenue of $48.3 million, meaning Ionis's own launches have not overtaken partner income more than a year into its independent commercial strategy. The slower-than-expected Tryngolza ramp is the single clearest evidence that the company cannot yet convert pipeline promise into its own P&L.
- Cash burn and leverage are severe: TTM free cash flow is -$616.3 million, Q3 operating cash flow was -$179.4 million, and cash fell to $296.3 million from $782.6 million. Debt-to-equity of 5.35 and total debt-to-capitalization of 84.5% mean a dilutive financing is a live risk if the burn persists.
- Losses widening despite revenue growth: Q3 2026 EPS of -$0.66 widened from -$0.56 in Q1 even as revenue grew, because operating expenses of $370.1 million are expanding faster than gross profit. The -40.47% operating margin and -40.36% net margin show no near-term path to breakeven without a major milestone.
- Technical collapse with no base: The stock is down 58.39% over one year and 63.52% YTD, sitting at just 3.0% of its 52-week range with a -68.43% max drawdown. The 1-month decline of -31.94% is steeper than the 3-month -49.23%, meaning the rate of decline is accelerating rather than stabilizing.
IONS Technical Analysis
Ionis is locked in a severe, sustained downtrend: the stock is down 58.39% over the trailing year and 63.52% year-to-date, and at $29.06 it trades at just 3.0% of its 52-week range (low $27.25, high $86.74) — essentially pinned to its lows. That positioning is the signature of a falling knife rather than a value entry: the stock has surrendered roughly two-thirds of its peak value and shows no structural base, with a maximum drawdown of -68.43% confirming the depth of the collapse. Momentum is unambiguously negative and still deteriorating. The 1-month change of -31.94% is worse than the 3-month change of -49.23%, which is in turn worse than the 6-month change of -60.85%, meaning the rate of decline has accelerated into the present rather than stabilized — a classic capitulation pattern. The most recent session did print a +6.41% bounce off the $27.25 low, but that is a single-day reflex within a waterfall decline, and relative strength versus the S&P 500 is catastrophic across every window (-29.68% over 1 month, -70.66% over 1 year), underscoring that this is idiosyncratic company-specific damage, not market beta. Key levels are stark: the $27.25 52-week low is the only visible support, and a decisive break below it would open fresh downside with no historical reference points, while resistance sits far overhead at the $86.74 high, with intermediate supply likely clustered around the $40-$45 shelf where the stock consolidated in October before the November gap-down. Volatility is a paradox here — the reported beta of 0.404 suggests low market sensitivity, but the realized price action (a drop from $86.33 on July 7 to $29.06 by mid-November) reflects extreme idiosyncratic, event-driven volatility that beta fails to capture; position sizing should be governed by the binary catalyst risk, not the misleadingly low beta. The short ratio of 8.0 days-to-cover signals heavy bearish positioning that could fuel sharp squeezes on any positive catalyst, adding two-way risk.
Beta
—
—
Max Drawdown
-69.3%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-63.6%
Cumulative gain past year
| Period | IONS Return | S&P 500 |
|---|---|---|
| 1m | -40.0% | -9.7% |
| 3m | -55.5% | -9.9% |
| 6m | -64.8% | -7.5% |
| 1y | -63.6% | +4.7% |
| ytd | -66.6% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IONS Fundamental Analysis
Revenue is growing robustly at the top line but is lumpy and partnership-dependent: Q3 2026 revenue of $242.7 million rose 54.88% year-over-year versus $156.7 million in Q3 2025, yet it declined sequentially from Q2's $267.9 million and Q1's $246.1 million. The segment mix reveals the core tension — royalties of $80.6 million still exceed product revenue of $48.3 million, meaning the company's own commercial launches (Tryngolza, Dawnzera) have not yet overtaken partner-derived income, consistent with the reported slower-than-expected Tryngolza ramp. The multi-quarter trend is choppy rather than compounding: revenue swung from $452.0 million in Q2 2025 (a milestone-rich quarter) down to $203.0 million in Q4 2025 and back up through 2026, which makes the 54.88% YoY growth rate flattering and dependent on milestone timing rather than a clean commercial trajectory. Profitability remains elusive despite a pristine gross margin of 98.63% (gross profit of $239.4 million on $242.7 million of revenue), a hallmark of the biotech royalty model where cost of revenue is trivial. The company posted a Q3 2026 net loss of $110.0 million (EPS -$0.66), an operating loss of $130.7 million, and an operating margin of -40.47%, driven by $215.9 million of R&D and $154.2 million of SG&A — the cost base of a company funding both a broad pipeline and a commercial build-out. Losses have widened on a per-share basis through 2026 (from -$0.56 in Q1 to -$0.66 in Q3) even as revenue grew, because operating expenses of $370.1 million are expanding faster than gross profit, and the trailing net margin of -40.36% shows no near-term path to breakeven without either a major milestone or a commercial inflection. The balance sheet is the strongest part of the story: a current ratio of 3.83 and quick ratio above 5 provide substantial near-term liquidity, but leverage is high with debt-to-equity of 5.35 and total debt-to-capitalization of 84.5%, and the company is burning cash — trailing twelve-month free cash flow of -$616.3 million and Q3 operating cash flow of -$179.4 million. ROE of -77.9% and ROA of -11.9% reflect both the losses and a thin equity base levered by debt, meaning Ionis depends on its cash reserves ($296.3 million at Q3 end, down from $782.6 million) and capital markets access to fund operations; the absence of a dividend and negative FCF yield confirm this is a pure reinvestment story with financing risk if the burn persists.
Quarterly Revenue
$242721000.0B
2026-09
Revenue YoY Growth
+54.9%
YoY Comparison
Gross Margin
98.6%
Latest Quarter
Free Cash Flow
$-616262000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IONS Overvalued?
Because Ionis is loss-making (trailing EPS of -$0.03, Q3 net loss of $110.0 million, negative EBITDA of -$97.0 million), the PE ratio is not meaningful — the trailing PE of -33.24 and forward PE of -16.48 are artifacts of negative earnings, and EV/EBITDA of -52.41 is equally unusable. I therefore anchor on the price-to-sales ratio of 13.41x and EV/Sales of 5.28x, which are the appropriate metrics for a pre-profit biotech with high gross margins; the wide gap between the 13.41x equity P/S and the 5.28x EV/Sales reflects the heavy debt load embedded in enterprise value. Notably, the forward PE of -16.48 versus trailing -33.24 implies the market expects losses to roughly halve, and consensus 2027 EPS estimates of $3.39 (range $2.40-$4.91) imply the Street models a swing to profitability — a forecast the current -40% net margin makes highly uncertain. On relative valuation, the 13.41x P/S sits well below the stock's own recent history but still represents a meaningful premium to mature biotech peers, and the 25.88x price-to-book is extreme for a company with negative returns on equity, reflecting how far book value has been eroded. The most telling comparison is internal: P/S has compressed from 63.13x at year-end 2025 and 67.11x in Q3 2025 to 13.41x today, a roughly 80% de-rating that mirrors the stock's collapse and suggests the market has aggressively reset expectations for the commercial ramp. Against its own historical band, the current 13.41x P/S is near the low end of the multi-year range (which has spanned roughly 9x to 67x), and the 25.88x P/B, while high in absolute terms, is below the 29.83x seen in Q2 2026 — so the stock is cheap relative to its own history but not obviously cheap on absolute sales multiples given the execution risk. The PEG ratio of 1.53 offers little comfort because it rests on forward earnings that do not yet exist; until Ionis demonstrates a credible path to the consensus $3.39 EPS, the valuation is a bet on pipeline optionality rather than a defensible earnings multiple.
PE
-33.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
29.3x
Industry PE ~29.3x*
EV/EBITDA
-52.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risk is acute. Ionis burned $616.3 million of free cash flow over the trailing twelve months, with Q3 operating cash flow of -$179.4 million, while cash fell from $782.6 million to $296.3 million — a trajectory that implies a financing event within roughly four to six quarters absent a large milestone. Leverage compounds the problem: debt-to-equity of 5.35 and total debt-to-capitalization of 84.5% mean the equity base is thin, and ROE of -77.9% reflects both the losses and that leverage. Revenue is also concentrated and lumpy — Q3's 54.88% YoY growth flatters a sequential decline from Q2's $267.9 million, and royalties of $80.6 million still exceed the $48.3 million of product revenue, so the P&L remains hostage to partner milestone timing rather than a clean commercial ramp. Market and competitive risk centers on valuation compression and execution credibility. At 13.41x P/S the stock is near the low end of its own 9x-67x historical band but still at a premium to mature biotech peers, and the 25.88x P/B is extreme for a negative-ROE business — so further de-rating is possible if the commercial build-out disappoints. The reported beta of 0.404 understates true risk: the stock fell from $86.33 on July 7 to $29.06 by mid-November, a collapse driven by idiosyncratic events (the 2026 cardiovascular pipeline failure, the Tryngolza miss, Arrowhead competition) that beta cannot capture. Heavy short interest at 8.0 days-to-cover adds two-way volatility, and the November 9-10 analyst reiterations largely embed pre-selloff assumptions, so downgrades remain a live catalyst. The worst-case scenario is a chain in which Tryngolza and Dawnzera both plateau below expectations, a partnered Phase III program fails and removes milestone income, and the cash burn forces a dilutive equity raise at depressed prices — each step reinforcing the others. Quantitatively, a retest of the $27.25 52-week low is only -6.2% from $29.06, but a decisive break below it opens fresh downside with no historical reference, and a move toward the -68.43% max-drawdown profile or a financing at a discount could take the stock into the low-$20s, roughly -25% to -30% from here. The $41.00 analyst low target offers no downside protection because it sits 41% above the current price, confirming that published models are not the binding constraint on this stock.
FAQ
The most severe is financing risk: TTM free cash flow of -$616.3 million and Q3 operating cash flow of -$179.4 million against $296.3 million of cash, with debt-to-equity at 5.35, make a dilutive equity raise the dominant near-term variable. Second is commercial execution risk, evidenced by product revenue of $48.3 million still trailing royalties of $80.6 million and a slower-than-expected Tryngolza ramp against Arrowhead competition in FCS. Third is pipeline binary risk — a partnered Phase III failure would remove milestone and royalty income that the P&L depends on, and the 2026 cardiovascular setback already demonstrated how quickly that repricing happens. Fourth is market and sentiment risk: the stock is down -58.39% over one year with a -68.43% max drawdown, short interest at 8.0 days-to-cover, and analyst targets that largely predate the November selloff, so downgrades and momentum remain live threats despite a reported beta of only 0.404.
The scenario work assigns 50% to a base case of $41-$55, in which launches grow but not fast enough to close the cash-burn gap and a modestly dilutive raise caps upside near the $41.00 analyst low and the October consolidation shelf. The 25% bull case targets $68-$105, requiring Dawnzera to sustain its early growth, Tryngolza to inflect as FCS diagnosis and reimbursement broaden, and partnered Phase III wins to convert into milestone cash, re-rating the stock toward the $68.48 average target. The 25% bear case targets $20-$27.25, in which both launches plateau, a partnered program fails, and a steep-discount raise breaks the $27.25 low with no historical support beneath it. The base case is most likely because the operating data — widening per-share losses and product revenue trailing royalties — point to a financing event rather than either a violent re-rating or a collapse.
Earnings-based multiples are unusable because Ionis is loss-making — trailing PE of -33.24, forward PE of -16.48, and EV/EBITDA of -52.41 are artifacts of negative earnings — so the relevant anchor is the 13.41x P/S and 5.28x EV/Sales, the latter lower because of the heavy debt load. Against its own history that is cheap: P/S has compressed from 63.13x at year-end 2025 and 67.11x in Q3 2025, putting today's multiple near the low end of a roughly 9x-67x multi-year band. In absolute terms it is not obviously cheap for a company with a -40.36% net margin and negative free cash flow, and the 25.88x P/B is extreme given a -77.9% ROE. The market is therefore pricing continued commercial disappointment and financing risk rather than platform value — a discount to history that only closes if the consensus $3.39 2027 EPS becomes credible.
From a pure risk/reward standpoint the setup is asymmetric but unproven: the $68.48 average target implies roughly +136% upside and even the $41.00 low target is 41% above the $29.06 price, while the nearest hard downside is the $27.25 52-week low only about 6% below — but a break there opens the low-$20s, roughly -25% to -30%. The reward case rests on a validated platform (98.63% gross margin, two partnered Phase III wins, a Zanvastro approval) rather than on demonstrated commercialization, since product revenue of $48.3 million still trails royalties of $80.6 million. The biggest downside risk is a dilutive equity raise forced by a -$616.3 million TTM cash burn against $296.3 million of cash, which would cap upside precisely when the stock is cheapest. It is a reasonable buy only for risk-tolerant investors with a multi-year horizon who size the position for a binary financing or pipeline event, and a poor fit for anyone needing earnings visibility or capital preservation.
This is a long-horizon holding at the science level but a short-fuse trading vehicle at the equity level, and the two should not be confused. The platform is in an early commercial stage — two 2025 launches, royalties still exceeding product revenue, no dividend, and a 0% payout ratio — so value creation depends on multi-year execution that a single quarter cannot resolve. Yet near-term volatility is extreme and idiosyncratic: the stock fell from $86.33 on July 7 to $29.06 by mid-November, a move the 0.404 beta completely fails to capture, and the 8.0 days-to-cover short interest guarantees sharp reactions to news. A concrete minimum holding period of 18-24 months is appropriate to span the next financing, several quarterly launch prints, and partnered milestone readouts; anyone with a shorter window is effectively trading a binary event rather than investing in the platform.

